JSLL

Jeena Sikho share price & financials

Price
₹557.2
Market cap
₹6.5k Cr
Sector
Consumer Services
Calls analysed
7
Latest concall · Q1 FY27 · call held 10 Aug 2026

Jeena Sikho Q1 FY27

Revenue from Operations ₹224 cr +29%EBITDA ₹92 cr +17%EBITDA Margin 41% PAT ₹65 cr

What went well

  • Revenue from operations grew 29% YoY to ₹224 crores in Q1 FY27.
  • EBITDA grew 17% YoY to ₹92 crores, maintaining a healthy 41% margin.
  • PAT reached ₹65 crores, with a 28% margin.

What to watch

  • Quarter-on-quarter revenue appeared flat, though management attributed this to strategic reduction in government business.
  • A significant portion of the 'other income' (₹7 crores out of ₹14 crores) was one-time, from warrant valuation and capital gains.
Read the full call →

What Jeena Sikho does

Jeena Sikho Lifecare runs a dual-vertical Ayurveda healthcare business: a nationwide network of hospitals, clinics and day-care centres delivering in-patient, out-patient, Panchakarma and home-based therapy services, alongside a separate Ayurvedic products business selling ~330 SKUs of herbal formulations under the 'Shuddhi' brand. Facilities operate on a hub-and-spoke model, pairing large owned Ayurveda hospitals with smaller company-run and franchisee-operated clinics and day-care centres; at franchisee sites, Ayurveda doctors remain on JSLL's payroll and medicines are supplied exclusively by JSLL. Products are sold through the company's own healthcare centres, tele-calling and e-commerce channels, and to franchisees, with manufacturing outsourced to a network of third-party manufacturers. The company is empanelled with several state government health schemes, CGHS/CAPF/ECHS, central armed police forces and private insurers for patient billing.

Segments

  • Ayurveda Healthcare Services
  • Ayurveda Healthcare Products
Operational hospitals
61
Operational clinics & day-care centres
58
Total bed capacity (operational + pipeline)
2,861 beds (2,300 operational, 445 in pipeline)
States covered
23
Cities & towns covered
100+
SKUs in Ayurveda medicine & product portfolio
330+
Founded 2009Headquarters Zirakpur, Punjab, India Company website

Guidance record · Q1 FY27

what the last two calls moved 22 tracked 5 delivered 3 missed 14 open
  • FY25 Revenue delivered said Q2 FY25 Promised: INR450 crores Q1 FY27: No new information. Promise concluded.
  • FY25 PAT Margin missed said Q2 FY25 Promised: 25% Q1 FY27: No new information. Promise concluded.
  • Occupancy Rate at risk said Q4 FY25 Promised: 70-80% Q1 FY27: Occupancy for the quarter was 59%. Management reiterated the target: 'And I have to take the occupancy to 75%,80%.'

All 22 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 28.7%, net profit up 29.4% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue114 116 139 174 190 +67%222 +91%216 +55%224 +29%
EBITDA40 30 46 79 92 +130%101 +237%78 +70%92 +16%
Net profit27 13 25 51 59 +119%67 +415%45 +80%66 +29%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −32.9% 1Y

₹500₹600₹700₹800Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 7 Nov 2025Q3 FY26 — 9 Feb 2026Q4 FY26 — 2 Jun 2026Q1 FY27 — 10 Aug 2026

1Y: ₹762.7 on 10 Sept 2025 → ₹511.85. High ₹837.95 (17 Sept 2025), low ₹492.2 (1 Jun 2026).

How the price took the results

close before → close after

Q1 FY27
−9.7%
10 Aug
Q4 FY26
+20.0%
2 Jun
Q3 FY26
+4.0%
9 Feb
Q2 FY26
+1.1%
7 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 71.0% a year over 1 year, FY25 to FY26. Operating margin widened to 43.6%.

Year endingFY25FY26
Revenue₹469 Cr₹802 Cr
Operating profit₹141 Cr₹350 Cr
Operating margin30.1%43.6%
Interest₹10 Cr₹13 Cr
Depreciation₹28 Cr₹47 Cr
Net profit₹81 Cr₹222 Cr
Net margin17.3%27.7%
Cash from operations₹69 Cr₹262 Cr
Free cash flow₹-40 Cr₹231 Cr
ROCE50.0%71.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹0 Cr₹10 Cr₹14 Cr₹25 Cr₹25 Cr₹25 Cr
Reserves₹24 Cr₹26 Cr₹112 Cr₹167 Cr₹329 Cr₹443 Cr
Borrowings₹12 Cr₹7 Cr₹1 Cr₹1 Cr₹106 Cr₹127 Cr
Other liabilities₹13 Cr₹18 Cr₹24 Cr₹28 Cr₹86 Cr₹78 Cr
Total liabilities₹49 Cr₹62 Cr₹151 Cr₹221 Cr₹546 Cr₹673 Cr
Fixed assets₹23 Cr₹28 Cr₹60 Cr₹67 Cr₹261 Cr₹307 Cr
Capital work in progress₹0 Cr₹5 Cr₹1 Cr₹4 Cr₹17 Cr₹2 Cr
Investments₹0 Cr₹0 Cr₹5 Cr₹4 Cr₹92 Cr₹95 Cr
Other assets₹26 Cr₹28 Cr₹86 Cr₹146 Cr₹176 Cr₹269 Cr
Total assets₹49 Cr₹62 Cr₹151 Cr₹221 Cr₹546 Cr₹673 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs trimmed −1.13 pp while the public added +0.86 pp. The shareholder count grew 557% to 43,413.

Promoters
63.6%
FIIs
4.8%
DIIs
0.4%
Public
31.2%

Since Jun 2025

  • FIIs −1.13 pp
  • Public +0.86 pp
  • DIIs +0.18 pp

How it drifted, 12 quarters

Over this window FIIs went from 0.0% to 4.8% — +4.8 pp.

Sep '22Sep '24Jun '26

Ownership split by quarter, oldest first. Sep '22: Promoters 65.9%, Public 34.1%.Mar '23: Promoters 66.2%, Public 33.8%.Sep '23: Promoters 67.9%, FIIs 2.0%, DIIs 0.0%, Public 30.1%.Nov '23: Promoters 67.9%, FIIs 1.8%, Public 30.3%.Mar '24: Promoters 67.9%, FIIs 0.3%, Public 31.8%.Sep '24: Promoters 65.8%, FIIs 4.0%, DIIs 0.1%, Public 30.0%.Mar '25: Promoters 63.5%, FIIs 6.0%, DIIs 0.2%, Public 30.3%.Jun '25: Promoters 63.5%, FIIs 5.9%, DIIs 0.2%, Public 30.4%.Sep '25: Promoters 63.6%, FIIs 6.6%, DIIs 0.1%, Public 29.6%.Dec '25: Promoters 63.6%, FIIs 6.3%, DIIs 0.1%, Public 30.0%.Mar '26: Promoters 63.6%, FIIs 6.2%, DIIs 0.5%, Public 29.8%.Jun '26: Promoters 63.6%, FIIs 4.8%, DIIs 0.4%, Public 31.2%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Jeena Sikho above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Manish Grover 63.27%unchanged
Sixteenth Street Asian Gems Fund FPI fund4.20%−1.46 pp
Oregano Life Private Limited 2.95%−0.82 pp
Ajay Kumar Aggarwal - 2 1.68%unchanged
Bhavna Grover 0.20%unchanged
Rohit Grover 0.06%unchanged
Mukesh Grover 0.04%unchanged
Santosh Grover 0.02%unchanged
Sahil Jain 0.01%unchanged
Shreya Grover 0.01%unchanged
Akansha Jain 0.01%unchanged
Madhav Grover 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Attractive

To justify its price of ₹512, this stock must grow earnings at 19% every year for 7 years. Our analysis caps realistic growth at ~173%. At that growth it is worth ₹133827 — upside of 26046%.

Growth the price implies
19.1% a year
for 7 years, fading to 4%
It has actually compounded at
174.1% a year
net profit, FY25–FY26 · EPS 173.4%
The gap
-1.5 pp
26046% downside if it only repeats history
Price today ₹511.85 Value at the reference growth ₹1,33,826.6

Change the assumptions yourself →

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse Jeena Sikho

Guides on how to read this kind of business and the numbers that matter.